The ePlex approval in Europe has resulted in strong interest and customer adoption
US FDA approval on track this year with imminent launch
Core business trends remain strong
Making inroads to competitive accounts and green field placements as well
Enjoy the ride longs, your patience has paid off
GNMK has seen strong interest in the EU market, having secured
15 customer orders and will look to ramp up placements heading into the back half of
2016. Although GNMK faces competition in Europe with bioMerieux/, I believe the
syndromic (multiplex) infectious disease panel market remains in early innings and will
likely take about 3-5 years or so to gain maturity, in our view. As a result, I expect more
than 1 winner in the marketplace, and GNMK to have considerable sales traction and runway.
Sentiment: Strong Buy
I live for my dream and a pocketful of gold
They have game enough. My model projects them earnings 200m in sales in 2018. By that time, the US launch will be in full swing along with a full panel of tests. The test sites in Europe have been very positive, and the company is sitting on a lot of pre-orders. They have a differentiated offering and a large addressable market. My price target is $18.
GNMK has been heavily targeted by the shorts due to a series of delays in launching its revolutionary ePlex molecular diagnostics system. At this point, the shorts face over a month to cover should good news hit the tape. My careful reading of recent management commentary coupled with new disclosures on its web site today, I am convinced that GNMK is on the verge of gaining CE mark approval in Europe with a full-scale product launch to follow. This will be an enormous boost to the stock. The large hedge funds which have mis-calculated that this event would ever occur are now in very deep trouble. The stock is very thinly traded and the committed longs know what they own and will not sell to the shorts attempting to cover.
Stay tuned folks